RxDoctor Payments DataLook up a doctor →

Shiv Saidha

Neurology · Baltimore, MDNPI 1245568740

Payments from drug & device makers

$2,127,523in general payments, 2019–2025

Across 331 payments — averaging $6427.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1M
  • Biogen$484K
  • Novartis$441K
  • Genentech USA, Inc.$56K
  • EMD Serono, Inc.$40K
  • Sanofi$26K
  • plus $35K from 6 others
$7,574in research payments, 2019–2025

Across 4 payments — averaging $1893.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$8K

What the payments were for

  • Consulting fees$253,44985%
  • Speaking & faculty fees$18,4236%
  • Travel & lodging$16,1495%
  • Food & beverage$9,3693%
  • Education$1520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.20$1,044,897
Biogen100$484,042
Novartis51$441,353
Genentech USA, Inc.58$56,007
EMD Serono, Inc.30$40,022
Sanofi23$25,715
Bristol Myers Squibb16$11,367
TG Therapeutics, Inc.14$7,334
Amgen(2 entities)14$6,537
Carl Zeiss Meditec, Inc.1$5,400
Kiniksa Pharmaceuticals, Ltd.3$2,450
E.r. Squibb & Sons, L.L.C.1$2,400

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,127,523 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$22,103
Medicare patients
140
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab16$227,122
CopaxoneGlatiramer Acetate12$83,383
AmpyraDalfampridine20$81,619
TecfideraDimethyl Fumarate11$46,924
Dalfampridine ErDalfampridine39$19,939
Emgality PenGalcanezumab-Gnlm15$9,811
Gabapentin61$2,572
Baclofen59$1,473
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$985
Duloxetine Hcl46$778
Modafinil18$600
Venlafaxine Hcl ErVenlafaxine Hcl17$511
Methylphenidate ErMethylphenidate Hcl13$452
Clonazepam22$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$484,042$46,92411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →